Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy - Wikidata - awgldk - TriplyDB

Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy

Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy

http://www.wikidata.org/entity/Q24657470

about

Aldosterone antagonists for preventing the progression of chronic kidney disease Recent advances in managing and understanding diabetic nephropathy Drug Targets for Oxidative Podocyte Injury in Diabetic Nephropathy Present and future in the treatment of diabetic kidney disease Mineralocorticoid receptor blockade in chronic kidney disease Antihypertensive treatment and renal protection: the role of drugs inhibiting the renin-angiotensin-aldosterone system Therapeutic targeting of aldosterone: a novel approach to the treatment of glomerular disease Therapeutic modalities in diabetic nephropathy: standard and emerging approaches.Diabetic kidney disease: a report from an ADA Consensus Conference Aldosterone synthase inhibition in humans Diabetic kidney disease: from physiology to therapeutics Is there a new dawn for selective mineralocorticoid receptor antagonism?Improvements in the Management of Diabetic Nephropathy AS101 prevents diabetic nephropathy progression and mesangial cell dysfunction: regulation of the AKT downstream pathway Diabetic nephropathy - Epidemiology in Asia and the current state of treatment Management of Diabetic Nephropathy in the Elderly: Special Considerations.Clinical therapeutic strategies for early stage of diabetic kidney disease.Long-term effects of spironolactone in peritoneal dialysis patients Data and Safety Monitoring Board evaluation and management of a renal adverse event signal in TOPCAT.The impact of antihypertensives on kidney disease.Mineralocorticoid Receptor Signaling as a Therapeutic Target for Renal and Cardiac Fibrosis.Moderate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study.Mineralocorticoid receptor antagonists and the metabolic syndrome Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis.Spironolactone rescues Dot1a-Af9-mediated repression of endothelin-1 and improves kidney injury in streptozotocin-induced diabetic rats Advances in treatment of hyperkalemia in chronic kidney disease.Dual renin-angiotensin-aldosterone system blockade for diabetic kidney disease.Genetic Predisposition to Diabetic Nephropathy: Evidence for a Role of ACE (I/D) Gene Polymorphism in Type 2 Diabetic Population from Kutch Region Aldosterone and glomerular filtration--observations in the general population New insight into the molecular drug target of diabetic nephropathy.Inhibition of RAS in diabetic nephropathy.Effective antihypertensive strategies for high-risk patients with diabetic nephropathy.Quantifying the effects of diuretics and β-adrenoceptor blockers on glycaemic control in diabetes mellitus - a systematic review and meta-analysis.Epigenetics in diabetic kidney disease.Albuminuria is Not an Appropriate Therapeutic Target in Patients with CKD: The Con View The kidney in type 2 diabetes therapy The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism.The central mechanism underlying hypertension: a review of the roles of sodium ions, epithelial sodium channels, the renin-angiotensin-aldosterone system, oxidative stress and endogenous digitalis in the brain.A method for isolation and identification of urinary biomarkers in patients with diabetic nephropathy.Hypertension Management in Diabetic Kidney Disease

P2860

Q24194979-1E1A1A47-41A0-4A4E-87E0-556A433D2648 Q26745900-1EAABB07-11BA-41FB-94B9-1FA203CC77CD Q26769787-D6D507CA-D22B-4771-86D0-2D8BEC306628 Q26864133-4D8EA973-7F59-440B-9C62-AD5A4CC9937B Q26864370-F6523FAB-0540-4E05-9D58-8C7B1BFBBDFA Q26865691-AF373E19-6888-40AC-9AC7-909FF0276064 Q26996385-4E95F574-E72D-4431-A224-160632B27C77 Q27007027-666430BB-D5FA-4FF2-87EE-BA3B3336045A Q27012546-E705EB4A-B0AA-4E67-8F36-39139FCB2416 Q27016157-BA2E0F79-B6BF-4DD3-8292-AE49955F2404 Q27021392-2B05FA18-9DFE-4DE7-8DA4-E896468902D4 Q27027792-776B0239-3B47-4D5B-9A0B-A0445D3FD67F Q28080717-6329C509-1AA4-4628-B854-7F4102BD7D05 Q28542507-F0A1CEFA-DEFF-4E57-82CE-6700E0EB8490 Q28742785-B162EA36-9265-4CB7-BF9A-3B43D70F1C13 Q30353386-C0B807CA-09AA-40EB-BE75-44CF8A7B9B2D Q30363683-8CAF53D6-700E-4DF6-900B-81B588AB613D Q30413119-1F723EE6-F263-4894-9F00-5CD8BFF8E6FD Q31143932-E289DECD-CD73-4CB9-93B4-36C38308AA95 Q33632021-D8606253-9E89-4C5F-9680-7CF7DDF3D769 Q33734806-88E6CB4D-B4E3-44C7-856D-9CA070B2444B Q34071671-2A7DA52F-7460-402A-B415-5780A6313359 Q34168923-803BA429-AF2C-42C6-BADE-254CB88BBA87 Q34380070-BB783C82-3ECB-40EB-A71E-06BC55676798 Q34450762-6AD1C3F4-27A7-4AAF-8ED6-6274EACA689E Q34491934-9B847C06-0D55-4DD6-9AA4-02852D2B0D70 Q34604473-18D9D1AE-88B3-490B-AA89-B51ACAC6E334 Q35028043-3737A556-960D-4413-A815-7A9E7E6214B5 Q35115799-18842BC4-0DE5-4582-9329-5921C5C3900A Q35125585-B447E3EB-D5DE-4A2D-A234-D250BC11AF4B Q35491275-6FE4DFF7-58DD-45F3-B3C5-1B451097CFF6 Q35546994-6B6C44C7-76F5-4438-B486-87075668F26D Q35557410-9D87838B-B0DA-461B-A1A5-53C00C49FBA1 Q35647853-51846C44-534E-47E2-B894-FFA651FD4995 Q35682234-78BC5C63-2A3E-4449-B559-74EA001B5A17 Q35760302-43EBD2BC-8279-40B5-AB69-12D22266C976 Q35834925-27B78711-D553-4691-97ED-D16E079743DC Q35883217-E5EB8875-D907-4BFC-BCDD-745D58370C55 Q35896647-B5261666-B465-4DFB-93E8-B9C6E539DF26 Q35953909-42740FD5-CD78-4D6E-AB3A-256BEEB880C5

P2860

Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy

http://www.wikidata.org/entity/Q24657470

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Addition of angiotensin recept ...... bition in diabetic nephropathy

@ast

Addition of angiotensin recept ...... bition in diabetic nephropathy

@en

Addition of angiotensin recept ...... bition in diabetic nephropathy

@nl

type

label

Addition of angiotensin recept ...... bition in diabetic nephropathy

@ast

Addition of angiotensin recept ...... bition in diabetic nephropathy

@en

Addition of angiotensin recept ...... bition in diabetic nephropathy

@nl

prefLabel

Addition of angiotensin recept ...... bition in diabetic nephropathy

@ast

Addition of angiotensin recept ...... bition in diabetic nephropathy

@en

Addition of angiotensin recept ...... bition in diabetic nephropathy

@nl

P1433

Q24657470-2E1E628F-BDBF-44AA-898A-A1D2FBD4080A

P1476

Q24657470-2A4CB516-5E13-4928-BB9F-C529D54A7E26

P2093

Q24657470-2B9CBF97-0FD6-413D-A90D-0D3841ABC754

Q24657470-6BE2B9D4-5428-4479-98FA-B4BBFE3D50CC

Q24657470-B8D9030C-3BD9-4A8F-8649-405E089DE7A8

Q24657470-C05EB7C4-6E1A-4238-AF10-0D03FD0E23FA

Q24657470-D22AE161-572B-497A-A48E-B18E1F675AC6

P2860

Q24657470-2C7FDE61-539C-49F9-BC3B-92A3B4057B3A

Q24657470-2EDF18A3-FAFA-48F0-8FF1-4509017BF4C5

Q24657470-370463CC-93B4-4948-B61A-2F232A079D43

Q24657470-44972AFC-AC5B-43BC-89DD-0C9B042C028E

Q24657470-44D89DC5-FBE9-4279-8404-58DAFFB50C8F

Q24657470-4832D4FE-18FA-452F-B29B-96AD1325AAAE

Q24657470-48A57448-0BA1-4CD0-8F43-24967EAA2A81

Q24657470-50B00F88-604E-411B-806C-514E980AD92D

Q24657470-53AC0B15-F367-4120-A6C6-0A2EC264C0F3

Q24657470-55EA59CF-3BC6-4ABC-9CD2-7DBFDE6BAC4F

P304

Q24657470-521E0F3F-2BCD-4097-B867-5CE8980FBE36

P31

Q24657470-E407D264-F785-4D2C-ACEC-437BDC1FC3AF

P3181

Q24657470-3BC371F7-C0D1-4B16-B5F9-CB7236A93957

P356

Q24657470-0DF518DD-DF14-4582-9594-C70CB4DA780E

P407

Q24657470-127889C8-012E-4072-96FD-C4060E523149

P433

Q24657470-6D39A422-0061-46BA-9339-7C0A1C6EE797

P478

Q24657470-191C9248-3AF4-41F3-8BD8-2D6171FC12B8

P577

Q24657470-D127D0DA-8A94-4397-829A-BA30772AC68C

P5875

Q24657470-DD3F5DA0-0E60-46F8-A4F4-1EA67AE9797A

P698

Q24657470-C96E3534-9C72-4A52-8BF3-BA45D4D8AEA9

P921

Q24657470-6A371615-5ED9-4B07-BF1A-5931C5338A07

P932

Q24657470-3A7E1169-6D88-47C7-B7F2-1010858BD821

P3181

P356

P1433

Journal of the American Society of Nephrology

P1476

Addition of angiotensin recept ...... bition in diabetic nephropathy

@en

P2093

Beverley Adams-Huet

http://www.w3.org/2001/XMLSchema#string

Gloria L Vega

http://www.w3.org/2001/XMLSchema#string

Philip Raskin

http://www.w3.org/2001/XMLSchema#string

Robert D Toto

http://www.w3.org/2001/XMLSchema#string

Uzma F Mehdi

http://www.w3.org/2001/XMLSchema#string

P2860

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study.

Aldosterone receptor blockade and the role of eplerenone: evolving perspectives.

Prognosis in diabetic nephropathy.

Aldosterone in the development and progression of renal injury.

The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology

Proteinuria reduction: mandatory consideration or option when selecting an antihypertensive agent?

P304

2641-50

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1188514

http://www.w3.org/2001/XMLSchema#string

P356

10.1681/ASN.2009070737

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P577

2009-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38114437

http://www.w3.org/2001/XMLSchema#string

P698

19926893

http://www.w3.org/2001/XMLSchema#string

P921

mineralocorticoid

P932

2794224

http://www.w3.org/2001/XMLSchema#string